Drug Trial Radar · NCT04155749
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
40
Actual
Start
Dec 23, 2019
Primary completion
Oct 3, 2024
Study completion May 2027
Sponsor
- Lead sponsor
- Kite, A Gilead CompanyGilead Sciences (GILD)
- Sponsor type
- Industry
- Collaborators
- Arcellx, Inc.
- First posted
- Nov 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.
Conditions
- Relapsed and Refractory Multiple Myeloma
Interventions
anitocabtagene-autoleucelDrug
Chimeric Antigen Receptor T cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs), including DLT(s)Time frame: 24 months
- Establish the RP2D of the investigational agentTime frame: 24 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Advanced Cellular Therapeutics Facility, DCAM 0800A
Chicago, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Froedtert Hospital/Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.